Chimerix, Inc. (NASDAQ:CMRX) will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.chimerix.com
Earnings Expectation
Chimerix, Inc. is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, CMRX to report 3Q20 loss of $ 0.17 per share. For the full year, analysts anticipate top line of $ 4.54 million, while looking forward to loss of $ 0.68 per share bottom line.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companys lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection.
